Intercos Valuation
Is 0AAR undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 0AAR when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 0AAR (€13.48) is trading above our estimate of fair value (€10.89)
Significantly Below Fair Value: 0AAR is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 0AAR?
Key metric: As 0AAR is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is 0AAR's PE Ratio? | |
|---|---|
| PE Ratio | 29.2x |
| Earnings | €45.13m |
| Market Cap | €1.32b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 1.4x |
| Enterprise Value/EBITDA | 13.2x |
| PEG Ratio | 1.3x |
Price to Earnings Ratio vs Peers
How does 0AAR's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 36.4x | ||
W7L Warpaint London | 24.7x | 11.8% | UK£423.7m |
APN Applied Nutrition | 25.5x | n/a | UK£347.5m |
VLG Venture Life Group | 66.8x | 67.1% | UK£49.6m |
HLN Haleon | 28.5x | 10.6% | UK£34.4b |
0AAR Intercos | 29.2x | 22.6% | €1.3b |
Price-To-Earnings vs Peers: 0AAR is good value based on its Price-To-Earnings Ratio (29.2x) compared to the peer average (36.4x).
Price to Earnings Ratio vs Industry
How does 0AAR's PE Ratio compare vs other companies in the European Personal Products Industry?
| 2 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 2 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: 0AAR is expensive based on its Price-To-Earnings Ratio (29.2x) compared to the European Personal Products industry average (22.5x).
Price to Earnings Ratio vs Fair Ratio
What is 0AAR's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 29.2x |
| Fair PE Ratio | 20.4x |
Price-To-Earnings vs Fair Ratio: 0AAR is expensive based on its Price-To-Earnings Ratio (29.2x) compared to the estimated Fair Price-To-Earnings Ratio (20.4x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | €13.48 | €18.13 +34.5% | 6.1% | €20.00 | €17.00 | n/a | 6 |
| Nov ’25 | €14.68 | €18.63 +26.9% | 4.1% | €20.00 | €17.50 | n/a | 6 |
| Oct ’25 | €15.92 | €18.72 +17.6% | 4.1% | €20.00 | €17.50 | n/a | 6 |
| Sep ’25 | €16.14 | €18.68 +15.8% | 4.2% | €20.00 | €17.50 | n/a | 6 |
| Aug ’25 | €16.34 | €18.35 +12.3% | 5.3% | €20.00 | €17.00 | n/a | 6 |
| Jul ’25 | €15.58 | €18.18 +16.7% | 5.2% | €20.00 | €17.00 | n/a | 6 |
| Jun ’25 | €15.92 | €18.18 +14.2% | 5.2% | €20.00 | €17.00 | n/a | 6 |
| May ’25 | €13.14 | €17.60 +33.9% | 8.6% | €20.00 | €15.50 | n/a | 6 |
| Apr ’25 | €13.36 | €17.68 +32.3% | 8.1% | €20.00 | €15.50 | n/a | 6 |
| Mar ’25 | €14.06 | €17.54 +24.7% | 8.2% | €20.00 | €15.50 | n/a | 6 |
| Feb ’25 | €14.57 | €17.36 +19.2% | 8.0% | €20.00 | €15.50 | n/a | 6 |
| Jan ’25 | €14.26 | €17.11 +20.0% | 9.1% | €20.00 | €15.50 | n/a | 6 |
| Dec ’24 | €13.74 | €17.11 +24.5% | 9.1% | €20.00 | €15.50 | n/a | 6 |
| Nov ’24 | €13.47 | €17.18 +27.5% | 9.5% | €20.00 | €15.50 | €14.68 | 6 |
| Oct ’24 | €12.98 | €17.44 +34.4% | 8.4% | €20.00 | €15.50 | €15.92 | 6 |
| Sep ’24 | €13.44 | €17.78 +32.3% | 7.4% | €20.00 | €15.50 | €16.14 | 6 |
| Aug ’24 | €15.56 | €17.93 +15.2% | 7.3% | €20.00 | €15.50 | €16.34 | 6 |
| Jul ’24 | n/a | €17.93 0% | 7.3% | €20.00 | €15.50 | €15.58 | 6 |
| Jun ’24 | €15.72 | €17.93 +14.0% | 7.3% | €20.00 | €15.50 | €15.92 | 6 |
| May ’24 | €16.50 | €16.17 -2.0% | 5.6% | €17.50 | €14.50 | €13.14 | 6 |
| Apr ’24 | €13.35 | €15.45 +15.8% | 6.7% | €16.50 | €14.00 | €13.36 | 6 |
| Mar ’24 | €13.04 | €14.75 +13.1% | 8.2% | €16.50 | €13.00 | €14.06 | 6 |
| Feb ’24 | €13.65 | €14.75 +8.1% | 8.2% | €16.50 | €13.00 | €14.57 | 6 |
| Jan ’24 | €12.48 | €14.23 +14.1% | 11.1% | €16.50 | €12.00 | €14.26 | 6 |
| Dec ’23 | €12.60 | €13.88 +10.2% | 10.8% | €16.50 | €12.00 | €13.74 | 5 |
| Nov ’23 | €10.84 | €14.14 +30.5% | 9.3% | €16.50 | €12.70 | €13.47 | 5 |
Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.
Discover undervalued companies
Ontex Group
€620.0m
Develops, produces, and supplies personal hygiene products and solutions for baby, feminine, and adult care in Belgium, the United Kingdom, the United States, Italy, France, and internationally.
0QVQ
€7.59
7D
2.4%
1Y
7.7%
McBride
UK£182.8m
Manufactures and sells private label household and personal care products to retailers and brand owners in the United Kingdom, Germany, France, Italy, Spain, rest of Europe, Asia-Pacific, and internationally.It operates through five segments: Liquids, Powders, Unit dosing, Aerosols, and Asia Pacific.
MCBL
UK£1.05
7D
3.5%
1Y
71.3%
Suominen Oyj
€174.5m
Manufactures and sells nonwovens as roll goods for wipes and other applications in Finland, the Americas, the rest of Europe, and internationally.
0M1M
€2.65
7D
0%
1Y
-47.8%